Skip to content

Healing Diabetic Foot Ulcers with Semaglutide

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524738-24-00
Enrollment
70
Registered
2026-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Brief summary

Time (in weeks) to wound closure in patients with a DFU using semaglutide versus standard of care treatment.

Detailed description

Rate of >50% reduction in ulcer surface area after 6 week of treatment between study groups (excluding newly formed ulcers), Ulcer surface area and depth at every outpatient clinic (relative to baseline), The change in ankle-brachial index/toe pressure measurements over time (at inclusion, and after wound closure of 6 months of follow-up), Rate of lower limb amputation, Rate of endovascular intervention in lower extremities, Rate of infection

Interventions

Sponsors

Radboud universitair medisch centrum Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Time (in weeks) to wound closure in patients with a DFU using semaglutide versus standard of care treatment.

Secondary

MeasureTime frame
Rate of >50% reduction in ulcer surface area after 6 week of treatment between study groups (excluding newly formed ulcers), Ulcer surface area and depth at every outpatient clinic (relative to baseline), The change in ankle-brachial index/toe pressure measurements over time (at inclusion, and after wound closure of 6 months of follow-up), Rate of lower limb amputation, Rate of endovascular intervention in lower extremities, Rate of infection

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 31, 2026